Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. (ACXP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ACXP · as of Sep 30, 2025
Ownership Breakdown
16
Institutional Holders
▼ 17 vs Q2
$245,741
Total Inst. Value
▼ $1.08M vs Q2
1.58M
Shares Outstanding
freeFloat 82.10%
63,133
13F Shares Held
▼ 2.55M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ACXP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
PROSPECT FINANCIAL SERVICES LLC pharmaceutical preparations | 19.9K | 1.22% | 1.22% | $85.30M | Nov 7, 2025 | NEW |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 16.8K | 1.03% | 1.03% | $72.14M | Nov 14, 2025 | NEW |
ADVISOR GROUP HOLDINGS, INC. pharmaceutical preparations | 7.6K | 63.70% | 63.70% | $2.43M | Nov 14, 2025 | ▼ 2.9K |
SABBY MANAGEMENT, LLC pharmaceutical preparations | 8.7K | 53.54% | 53.54% | $37.34M | Nov 14, 2025 | NEW |
MORGAN STANLEY pharmaceutical preparations | 5.3K | 32.66% | 32.66% | $22.78M | May 27, 2026 | NEW |
NBC SECURITIES, INC. pharmaceutical preparations | 1.5K | 9.23% | 9.23% | $6.43M | Nov 14, 2025 | NEW |
GPS WEALTH STRATEGIES GROUP, LLC pharmaceutical preparations | 1.2K | 7.53% | 7.53% | $5.26M | Nov 3, 2025 | NEW |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 1.1K | 6.62% | 6.62% | $4.62M | Nov 14, 2025 | NEW |
CITIGROUP INC pharmaceutical preparations | 453 | 2.79% | 2.79% | $1.94M | Nov 10, 2025 | NEW |
GROUP ONE TRADING, L.P. pharmaceutical preparations | 298 | 1.83% | 1.83% | $1.28M | Nov 12, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
0
Increased
+0 shares15
New Positions
first time holders2
Decreased
−3.0K shares30
Sold Out
fully exitedNet shares change (top 50)
3.0K
+0 / −3.0K
Net new holders
-17
15 new / 30 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ACXP insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
8
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Sailer Carl director | Apr 20, 2026 | Award | 2,150 | $2.36 | $5.1K | 2.1K | Form 4 ↗ |
DEAN JACK H director | Apr 20, 2026 | Award | 2,150 | $2.36 | $5.1K | 2.1K | Form 4 ↗ |
Donohue James J. director | Apr 20, 2026 | Award | 2,150 | $2.36 | $5.1K | 2.1K | Form 4 ↗ |
HARRISON THOMAS L director | Apr 20, 2026 | Award | 2,150 | $2.36 | $5.1K | 2.1K | Form 4 ↗ |
Scodari Joseph C director | Apr 20, 2026 | Award | 2,150 | $2.36 | $5.1K | 2.1K | Form 4 ↗ |
DELUCCIA ROBERT J director | Apr 20, 2026 | Award | 37,100 | $2.36 | $87.6K | 37.1K | Form 4 ↗ |
LUCI DAVID P President and CEO | Apr 20, 2026 | Award | 37,100 | $2.36 | $87.6K | 37.1K | Form 4 ↗ |
Shawah Robert G. Chief Financial Officer | Apr 20, 2026 | Award | 25,900 | $2.36 | $61.1K | 25.9K | Form 4 ↗ |
Shawah Robert G. Chief Financial Officer | Feb 5, 2025 | Award | 145,500 | $0.80 | $116.1K | 145.5K | Form 4 ↗ |
LUCI DAVID P President and CEO | Feb 5, 2025 | Award | 250,000 | $0.80 | $199.6K | 250.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Acurx Pharmaceuticals, Inc. (ACXP) is primarily owned by institutional investors, who hold approximately 4.0% of total shares outstanding. Company insiders own approximately 17.90%, while retail and public investors account for the remaining 78.11%.
The largest institutional shareholder of Acurx Pharmaceuticals, Inc. is PROSPECT FINANCIAL SERVICES LLC, holding approximately 19,883 shares — equal to 1.22% of outstanding shares — as of September 30, 2025.
A total of 16 institutional investors currently hold ACXP stock, with a combined institutional value of approximately $245,741 as of the most recent 13F filing period.
Frequently asked questions
ACXP ownershipAcurx Pharmaceuticals, Inc. (ACXP) is primarily owned by institutional investors, who hold approximately 4.0% of shares. The largest shareholder is PROSPECT FINANCIAL SERVICES LLC with a 1.22% stake. Company insiders hold 17.90%. Data sourced from SEC Form 13F as of September 30, 2025.